… disease in the late post-transplant period. On the other hand, … kidney transplant recipients
directly comparing valganciclovir … was designed to compare valganciclovir prophylaxis versus …

… treatment of cytomegalovirus infection and disease in solid organ and stem cell transplant
recipients… of ganciclovir and valganciclovir in transplant recipients have been published so far, …

… of valganciclovir in pediatric renal transplant recipients and … renal transplant who received
valganciclovir to prevent or treat … 104 patients aged 2 to 20 years treated with valganciclovir, …

… In conclusion, 450 mg of valganciclovir was effective in preventing CMV infection in kidney
transplant patients compared with the standard dose and showed the best rank probability. In …

… Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus
disease in solid organ transplant recipients.  Am J Transplant. 2004;4(4):611-620. doi:10.1111/j.…

… -risk liver transplant recipients receiving valganciclovir 450 mg … 2]; heart transplant recipients
receiving valganciclovir 900 mg … [3]; lastly, lung transplant recipients receiving valganciclovir …

… : age ≥18 years; had undergone SOT or HSCT; and were receiving ganciclovir IV or
valganciclovir PO as prophylaxis or treatment, having had TDM performed as a part of routine care. …

… abdominal transplant recipients with severe or persistent CMV infection, patients developed
… These data suggest that using letermovir in place of valganciclovir for secondary …

… to prevent CMV disease include the use of the antivirals ganciclovir (GCV) and the oral
prodrug valganciclovir (ValGCV), whilst foscarnet or cidofovir are used much less frequently.10-…

… It is unknown if kidney transplant recipients receiving valganciclovir prophylaxis exhibit …
valganciclovir prophylactic dosing and ganciclovir exposure in kidney transplant recipients …